Effects of Baduanjin exercise in alleviating symptoms of fibromyalgia syndrome: A randomized controlled trial.

Fibromyalgia syndrome causes widespread pain, fatigue, and sleep problems that can significantly impact daily life. Researchers in China studied whether Baduanjin—a gentle form of traditional Chinese exercise combining slow movements, breathing, and meditation—could help people with this condition. The study included 74 adults with fibromyalgia who were randomly divided into two groups. One group practiced Baduanjin exercises for 30 minutes daily under supervision for four weeks, while the other group received standard medical care. The researchers measured pain levels, sleep quality, fatigue, and overall disease impact at the beginning of the study, after four weeks, and again four weeks later. They also used special equipment to measure muscle activation objectively. After four weeks of practice, the Baduanjin group showed significant improvements in almost all areas compared to the control group. They experienced less pain, better sleep, reduced fatigue, and improved overall functioning. Muscle activation also increased, suggesting better physical conditioning. Some benefits, particularly regarding pain extent, sleep quality, and fatigue, lasted even four weeks after the exercise program ended. The exercise was safe, with only mild side effects reported. This study suggests that Baduanjin may be a valuable complement to conventional fibromyalgia treatment, offering a non-drug approach to managing symptoms. If you're interested in trying Baduanjin or other traditional Chinese mind-body practices for fibromyalgia, consult with a qualified practitioner certified in these therapeutic exercises.

This assessor-blinded RCT (n=74) evaluated Baduanjin exercise versus standard therapy for fibromyalgia syndrome over 4 weeks with 8-week follow-up. Participants (mean age 47.96 years, 55.41% female) performed supervised 30-minute daily Baduanjin sessions. At week 4, the intervention group demonstrated statistically significant improvements in primary outcome FIQR (MD -4.49 points, P=0.005) and all secondary measures: VAS pain (MD -0.78, P=0.037), WPI (MD -1.91, P<0.001), PSQI (MD -1.65, P=0.001), and MFI-20 fatigue (MD -4.74, P=0.001). Surface EMG showed increased muscle activation bilaterally (left +24.9 μV, right +26.4 μV; P=0.014 and P=0.038). At week 8, pain extent, sleep quality, and fatigue improvements persisted, though overall disease impact and pain intensity differences were no longer significant. No serious adverse events occurred. This study provides robust evidence supporting Baduanjin as a safe, effective complementary intervention for multidimensional FMS symptom management with sustained benefits in select domains.